[1] |
BADE B C, DELA CRUZ C S. Lung cancer 2020: epidemiology, etiology, and prevention[J]. Clin Chest Med, 2020, 41(1): 1-24.
doi: S0272-5231(19)30080-2
pmid: 32008623
|
[2] |
ZHOU Y Y, HÖTI N, AO M H, et al. Expression of p16 and p53 in non-small cell lung cancer: clinicopathological correlation and potential prognostic impact[J]. Biomark Med, 2019, 13(9): 761-771.
doi: 10.2217/bmm-2018-0441
|
[3] |
BRAIT M, MALDONADO L, NOORDHUIS M G, et al. Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression[J]. PLoS One, 2013, 8(9): e70878.
doi: 10.1371/journal.pone.0070878
|
[4] |
WANG K X, JI W X, YU Y F, et al. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer[J]. Oncogene, 2018, 37(39): 5340-5354.
doi: 10.1038/s41388-018-0311-3
pmid: 29858603
|
[5] |
WANG J, SHIVAKUMAR S, BARKER K, et al. Comparative study of autoantibody responses between lung adenocarcinoma and benign pulmonary nodules[J]. J Thorac Oncol, 2016, 11(3): 334-345.
doi: 10.1016/j.jtho.2015.11.011
pmid: 26896032
|
[6] |
ORLOVETSKIE N, SERRUYA R, ABBOUD-JARROUS G, et al. Targeted inhibition of WRN helicase, replication stress and cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1867(1): 42-48.
doi: 10.1016/j.bbcan.2016.11.004
|
[7] |
YI E, CHANG J E, LEEM C, et al. Association of MAGE A1-6 expression with lung cancer progression[J]. J Cancer, 2017, 8(8): 1324-1329.
doi: 10.7150/jca.18086
pmid: 28638445
|
[8] |
ZHANG X Z, LIU M, ZHANG X, et al. Autoantibodies to tumor-associated antigens in lung cancer diagnosis[J]. Adv Clin Chem, 2021, 103: 1-45.
doi: 10.1016/bs.acc.2020.08.005
pmid: 34229848
|
[9] |
XIAO K J, MA X L, WANG Y C, et al. Diagnostic value of serum tumor-associated autoantibodies in esophageal cancer[J]. Biomark Med, 2021, 15(15): 1333-1343.
doi: 10.2217/bmm-2021-0351
pmid: 34541870
|
[10] |
ZHANG R, MA L, LI W Y, et al. Diagnostic value of multiple tumor-associated autoantibodies in lung cancer[J]. Onco Targets Ther, 2019, 12: 457-469.
doi: 10.2147/OTT.S187734
|
[11] |
DU Q, YU R F, WANG H, et al. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer[J]. Clin Respir J, 2018, 12(6): 2020-2028.
doi: 10.1111/crj.12769
pmid: 29356386
|
[12] |
CHAPMAN C J, HEALEY G F, MURRAY A, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays[J]. Tumour Biol, 2012, 33(5): 1319-1326.
doi: 10.1007/s13277-012-0379-2
|
[13] |
CHAPMAN C J, MURRAY A, MCELVEEN J E, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure[J]. Thorax, 2008, 63(3): 228-233.
doi: 10.1136/thx.2007.083592
pmid: 17932110
|
[14] |
INFANTE M, CAVUTO S, LUTMAN F R, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial[J]. Am J Respir Crit Care Med, 2009, 180(5): 445-453.
doi: 10.1164/rccm.200901-0076OC
|
[15] |
PARRALES A, IWAKUMA T. Targeting oncogenic mutant p53 for cancer therapy[J]. Front Oncol, 2015, 5: 288.
doi: 10.3389/fonc.2015.00288
pmid: 26732534
|
[16] |
QIN J Y, ZENG N, YANG T, et al. Diagnostic value of autoantibodies in lung cancer: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018, 51(6): 2631-2646.
doi: 10.1159/000495935
pmid: 30562746
|
[17] |
NING Y C, HUI N, QING B, et al. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation[J]. Cell Death Dis, 2019, 10(6): 414.
doi: 10.1038/s41419-019-1635-9
pmid: 31138778
|
[18] |
SHAO L P, ZUO X L, YANG Y, et al. The inherited variations of a p53-responsive enhancer in 13q12.12 confer lung cancer risk by attenuating TNFRSF19 expression[J]. Genome Biol, 2019, 20(1): 103.
doi: 10.1186/s13059-019-1696-1
pmid: 31126313
|
[19] |
REN S X, ZHANG S C, JIANG T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population[J]. Oncoimmunology, 2018, 7(2): e1384108.
doi: 10.1080/2162402X.2017.1384108
|
[20] |
WEN W, LIU G, JIN K, et al. TGF-β1 induces PGP9.5 expression in CAFs to promote the growth of colorectal cancer cells[J]. Oncol Rep, 2017, 37(1): 115-122.
doi: 10.3892/or.2016.5238
pmid: 27840994
|
[21] |
LIN S C, CHOU Y T, JIANG S S, et al. Epigenetic switch between SOX2 and SOX9 regulates cancer cell plasticity[J]. Cancer Res, 2016, 76(23): 7036-7048.
doi: 10.1158/0008-5472.CAN-15-3178
|
[22] |
KAMEL L M, ATEF D M, MACKAWY A M H, et al. Circulating long non-coding RNA GAS5 and SOX2OT as potential biomarkers for diagnosis and prognosis of non-small cell lung cancer[J]. Biotechnol Appl Biochem, 2019, 66(4): 634-642.
doi: 10.1002/bab.1764
|
[23] |
TANG Z M, LING Z G, WANG C M, et al. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: a systematic review and meta-analysis[J]. PLoS One, 2017, 12(7): e0182117.
doi: 10.1371/journal.pone.0182117
|
[24] |
MU Y Y, XIE F Y, WANG F B, et al. Performance evaluation of an enzyme-linked immunosorbent assay for seven autoantibodies in lung cancer[J]. Clin Lab, 2019, 65(4).
|
[25] |
FANIPAKDEL A, SEILANIAN TOUSSI M, REZAZADEH F, et al. Overexpression of cancer-testis antigen melanoma-associated antigen A1 in lung cancer: a novel biomarker for prognosis, and a possible target for immunotherapy[J]. J Cell Physiol, 2019, 234(7): 12080-12086.
doi: 10.1002/jcp.27884
pmid: 30569450
|